ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects

Yahdiana Harahap1*, Budi Prasaja2, Windy Lusthom2, Hardiyanti2, Mena Bertony Ginting2 and Lipin2
1Bioequivalence Laboratory, Faculty of Pharmacy, University of Indonesia, Indonesia
2PT. Clinisindo Laboratories, Jakarta, Indonesia
Corresponding Author : Yahdiana Harahap
Faculty of Mathematic and Natural Sciences
University of Indonesia, Depok, West Java Indonesia
E-mail: yahdiana03@yahoo.com
Received April 18, 2012; Accepted May 24, 2012; Published May 26, 2012
Citation: Harahap Y, Prasaja B, Lusthom W, Hardiyanti, Ginting MB, et al. (2012) A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects. J Bioequiv Availab 4:048-051. doi: 10.4172/jbb.10000111
Copyright: © 2012 Harahap Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioequivalence & Bioavailability

Abstract

Aim: To compare the bioavailability of two Azithromycin tablet formulations 500 mg Azivol� tablets as test formulation and 500 mg Zithromax� tablets as reference formulation. Methods: A single-dosed, open-label, randomized two-way crossover design under fasting period with two weeks wash-out period was evaluated in 24 subjects. For the analysis of pharmacokinetic properties, the blood samples were drawn taken up to 120 hours after dosing. Plasma concentration of Azithromycin was determined using liquid chromatography � tandem mass spectrometry method with TurboIon Spray mode. Pharmacokinetic parameters AUC0-t, AUC0-∞ and Cmax were tested for bioequivalence after log-transformation of data and ratios of tmax were evaluated non-parametrically. Results: The point estimates and 90% confidence intervals (CI) for AUC0-t, AUC0-∞ and Cmax for Azithromycin were 94.63% (86.27-103.81%), 95.35% (87.15-104.31%), 94.16% (80.31-110.41%) respectively. Conclusion: These results indicated that the two formulations of Azithromycin were bioequivalent and thus may be prescribed interchangeably.

Keywords
Azithromycin; Antibiotic; Bioequivalence and Bioavailability; LC-MS/MS
Introduction
Azithromycin, 9-Deoxo-9a-aza-9a-methyl-9a-homoerythromycin a dihydrate, is a semi-synthetic 15-membered azalide antibiotics derived from erythromycin. Its chemical structure differs from that of erythromycin by the insertion of methyl-substituted nitrogen at position 9a in the lactone ring. This modification results in the improved acid stability associated with more reliable and greater oral bioavailability, more extensive tissue penetration, and significantly longer elimination half-life, which exhibits an extensive spectrum of activity compared with erythromycin. Azithromycin is effective against gram-positive and gram-negative pathogens. Due to its extensive tissue penetration and distribution, Azithromycin appears to be suitable antibiotic for the treatment and prophylaxis of respiratory tract infection, skin and softtissue infection, and sexually transmitted diseases [1,2].
Azithromycin given orally is rapidly absorbed from gastrointestinal track but is inhibited by food. Its absolute oral bioavailability is about 37%. Peak plasma concentrations are achieved 2 to 3 hours after a dose, but Azithromycin is extensively distributed to the tissues, and tissue concentrations subsequently remain much higher than those in the blood. Small amounts of Azithromycin are demethylated in the liver, and it is excreted in bile as unchanged drug and metabolites. Azithromycin metabolites are thought to possess no significant antimicrobial activity. About 6% of an oral dose (representing about 20% of the amount in the systemic circulation) is excreted in the urine. The terminal elimination half-life is about 68 hours [2-4].
As for erythromycin, gastrointestinal disturbances are the most frequent adverse effect but are usually mild and less frequent than with erythromycin. The central and peripheral nervous system, predominantly headache and dizziness may occur. Severe hypersensitivity reactions occur rarely but may be prolonged [2].
There are many generic products of Azithromycin in Indonesia and it must also go through the bioequivalence study in order to assure the efficacy, safety, and quality. The present study was conducted to investigate the pharmacokinetics and bioavailability of two Azithromycin tablet formulations in order to prove bioequivalence between both formulations.
Subjects and Methods
The protocol study was reviewed by the Committee of The Medical Research Ethics of the Faculty of Medicine, University of Indonesia (Jakarta, Indonesia) and was approved by the National Agency of Drug and Food Control (Jakarta, Indonesia). This study was conducted in compliance with the ethical principles of the Declaration of Helsinki for biomedical research involving human volunteers and Good Clinical Practice (GCP). All participants signed a written informed consent after they had been informed of the nature and details of the study in accordance with Indonesian Guidelines for Bioequivalence Studies [5,6].
The study was based on single-dose, open-label, randomized two-way crossover design under fasting period with two weeks wash out period. Subjects were randomized to one of the two sequences to receive the formulations according to randomization scheme. The test preparation was 500 mg of Azivol® tablets, manufactured by PT. Novell Pharmaceutical Laboratories, Indonesia (Batch no. 11D183) and the reference formulation was 500 mg Zithromax® tablets, produced by Pfizer Australia Pty Ltd., (Batch no. B914640151). The sample size n = 24 subjects was sufficient to ensure power of 80% for correctly concluding bioequivalence under the following assumption: a = 0.05, 0.95 < μT / μR < 1.05 and an intra-subject variability of 20% [7].
A total of 24 subjects (18 males and 6 females) were selected among Indonesia residents and participated in this study. The demographic data of twenty-four volunteers are shown in Table 1.
Subjects were selected after passing a clinical screening procedure including a physical examination, ECG and clinical laboratory tests (hemoglobin, hematocrit, WBC, platelets, WBC differential, blood urea nitrogen, sGPT, sGOT, alkaline phosphatase, total bilirubin, total protein, fasting glucose, albumin, creatinine, urine analysis, pregnancy test (for female subjects) and negative results of HBsAg, anti HBC and anti HIV. Volunteers were excluded if they had a history of any illness of the hepatic, renal and cardiovascular system, took alcohol or other medications for a long period of time, had hypersensitivity to Azithromycin, had received any investigation drug within four weeks (or suitable longer period for slowly eliminated drugs) of enrollment and donation or loss more than 450 ml of blood within 3 months prior to the screening of the study.
All subjects were avoided using other drugs for at least two weeks prior to the study and after its completion. They were also refrained from ingesting alcohol, caffeine, chocolate, tea or coke containing beverages at least 48 hours before each dosing and until the collection of the last blood sample. Subjects were confined to clinical unit of Clinisindo Laboratories one night before study to assure the fasting condition (10 hours before drug administration). On the study day, subjects were given one tablet of either product with 240 ml of water. No food was allowed until 4 hours after dose administration. Water intake was allowed 2 hours after the dose. Standard meals were served at 4 and 11 hours after drug administration. Snack was served at 8 hours after drug administration. Subjects were remained upright (sitting or standing) for the first 4 hours. Subjects were confined at clinical unit of Clinisindo Laboratories for 24 hours after dosing and were not permitted to take strenuous exercise during the sampling days. Blood pressure, heart rate, body temperature and adverse events were monitored during blood sampling. 5 ml of the venous blood were collected at pre dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours after drug administration in the heparinized tubes. After blood separation, plasma was frozen at -20°C until analysis. After two weeks wash out period, subjects returned to Clinisindo Laboratories and the blood sample analysis was repeated in the second period in the same manner to complete the crossover design.
Safety Evaluation
Analysis of safety-related data was considered using the more common adverse events which occurred after initiation of study treatment and supported by the following more detailed tabulations and analysis (Table 2).
LC-MS/MS assay of Azithromycin in plasma
The concentration of Azithromycin in plasma was determined using LC-MS/MS method with TurboIon Spray mode. Propranolol was used as the internal standard. The method has already been validated in terms of selectivity, sensitivity, linearity, accuracy and precision, recovery, stability, and also has been verified just before being used in study. The limit of quantification for Azithromycin was 2.0 ng/mL. The standard calibration curves for Azithromycin were ranged from 2-500 ng/mL. The best linear fit and least-squares residual for the calibration curve were achieved with 1/x2 weighing factor. The recoveries of Azithromycin were 84.54-87.91%. The analytical separation was performed on a Synergi 4 μ POLAR- RP-80A, 50 × 2.00 mm, 4 μm (Phenomenex®, USA) and protected by guard column AQ C18, 4 × 2.0 mm (Phenomenex®, USA). The mobile phase used gradient of 0.1% formic acid in acetonitrile and 0.1% formic acid in water, pumped 0.7 mL/min for 4.0 min run time. The column temperature was maintained at 40°C. Briefly, a 250 μL of human plasma in microtube was added with 20 μL of internal standard (10 ppm). After mixing, 250 μL of acetonitrile was added and vortex mixed for 30 seconds. The mixture was centrifuged at 3000 rpm for 10 min. A volume of 5 μL supernantant was injected into LC-MS/MS system. The retention time for Azithromycin and propranolol were 0.95 min and 1.10 min, respectively.
Pharmacokinetic and statistical analysis
The bioequivalence was determined using the primary parameters, AUC0-t, AUC0-∞, Cmax. Cmax and tmax were obtained directly by inspection of the individual drug plasma concentration time data, and were used as measures of rate of absorption. AUC0-t was calculated using the trapezoidal rule. The elimination rate constant (Kel) was calculated by the technique of least-squares regression from the data of the last 3-5 points of each plasma concentration data curve. The AUC0-∞ values were determined by adding the quotient of Ct and the appropriate Kel to the corresponding AUC0-t, that is:
AUC0-∞ = AUC0-t + Ct / Kel
The apparent elimination half-life (t½) of Azithromycin in plasma was calculated by using the following equation:
t½= (ln 2) / Kel
For the parameters of AUC0-t, AUC0-∞ and Cmax a multiplicative model was assumed, and analysis of variance (ANOVA) was applied using the respective ln-transformed data. For estimation of bioequivalence the 90% CI of the geometric mean ratio test/reference (T/R) for AUC0-t, AUC0-∞ and Cmax were calculated assuming a multiplicative model. The accepted bioequivalence range for these parameters was 80-125%. All statistical analyses were performed using Equiv Test version 2.0 software (Statistical Solution, Cork, Ireland).
Results and Discussion
Both Azithromycin formulations were well-tolerated at the administered dose and no significant adverse clinical events were observed. All adverse events were of mild intensity and recovered without concomitant medication. There were no serious adverse events. However, all events resolved completely. The disposition of adverse events is shown in Table 2.
The number register of this clinical trial is NCT 01602055. A total of 24 subjects participated in this study and all the subjects were available for pharmacokinetic evaluation. The Azithromycin concentration versus time profiles of twenty four subjects for both formulations are shown in Supplementary Figure 1 and the mean Azithromycin concentration versus time profiles for both formulations are shown in Figure 1. The pharmacokinetic parameters that are used to assess the bioequivalence of the test formulation versus the reference were AUC0-t, AUC0-∞ for the extent of the absorption and Cmax and tmax for the rate of absorption. Descriptive statistics of the pharmacokinetic parameter for Azithromycin test and reference are summarized in Table 3 where the geometric mean values and the range for the AUC0-t, AUC0-∞, Cmax and t½ values obtained for each formulation are shown. The pharmacokinetic characteristic tmax was presented as mean values. The mean obtained values for test and reference formulations were 586.64 and 623.51 ng/mL for Cmax; 4712.31 and 5016.39 ng.h/mL for AUC0-t; 5370.66 and 5711.19 ng.h/mL for AUC0-∞. The median tmax for test and reference formulations were 1.75 h and 2.25 h.
The results of the bioequivalence analysis for Azithromycin are given in Table 4. The intra-subject variability of Azithromycin in the AUC0-t, AUC0-∞, Cmax, and t½ estimates from the coefficient of variables as determined by ANOVA were 18.65%, 18.11%, 32.09%, and 11.53%, respectively. As shown in Table 4, 90% confidence intervals (CI) of AUCt, AUC0-∞, Cmax, and t½ log-transformed individual ratios of Azithromycin were included into the range of bioequivalence, i.e. 80-125% when analyzed by parametric statistics. In the same way, individual tmax difference was not statistically different between the two formulations. The mean ratio of AUC0-t/AUC0-∞ for all individuals and for both products was around 12%, indicate an adequate sampling time since the extrapolated portion of the total AUC is less than 20%. The results for t½ in the present study (50.50 ± 7.33 h for test product and 47.89 ± 7.23 h for reference product) were consistent with the results reported in the literatures (~ 40-50 h) [4,8,9].
In this research the variability of Cmax is high but from the previous research in healthy volunteers also showed that the intra-subject variability of Cmax can be as high as 34.7%. Azithromycin can therefore be considered as a highly variable drug. Highly variable drugs can therefore pose a problem in bioequivalence assessment using standard 0.8 – 1.25 approach. It is therefore justified from that point of view to use wider Cmax acceptance limits [10].
In conclusion, the application of either parametric or nonparametric statistics reveals the presence of bioequivalence between Azivol® FC tablet produced by PT. Novell Pharmaceutical Laboratories and Zithromax® FC tablet produced by Pfizer Australia Pty, Ltd for the rate and extent of absorption. Thus, it can be assumed that the two formulations are therapeutically equivalent and therefore interchangeable.
Acknowledgements
This study was supported by PT. Novell Pharmaceutical Laboratories, Jakarta, Indonesia.
References
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11713
  • [From(publication date):
    July-2012 - Aug 25, 2016]
  • Breakdown by view type
  • HTML page views : 7945
  • PDF downloads :3768
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version